The skincare industry is gradually expanding its understanding of healthy aging. Conventional anti-aging products have typically focused on correcting visible concerns such as wrinkles, fine lines and loss of firmness. While these outcomes remain important, the emerging concept of skin longevity introduces a broader objective: helping skin maintain its structure, barrier function and resilience over time.
This shift is influencing how cosmetic active ingredients are evaluated. Visible improvement alone does not provide a complete picture of skin condition. Product development increasingly considers whether an ingredient can also support the underlying qualities associated with long-term skin performance, including elasticity, moisture retention and barrier integrity.
A Broader Efficacy Profile
Uniproma’s recombinant PDRN has been developed in response to this evolving approach to skincare.
Its performance was evaluated in a 28-day in vivo study using a formulation containing the ingredient. The results demonstrated:
√ 46.67% reduction in wrinkle count
√ 30.11% increase in skin elasticity
√17.37% reduction in transepidermal water loss
Together, these results indicate activity across several interconnected dimensions of skin condition.
The reduction in wrinkle count demonstrates visible anti-aging performance. Increased elasticity is associated with improved structural resilience, while reduced transepidermal water loss indicates better barrier performance and moisture retention.
This combination extends the ingredient’s relevance beyond the conventional emphasis on visible wrinkle correction. By addressing appearance, elasticity and barrier function within the same efficacy profile, recombinant PDRN can support formulations developed around the broader concept of skin longevity.
Recombinant Biotechnology for Scalable Skincare Development
The production pathway is also an important part of the ingredient’s value.
Uniproma’s recombinant technology provides an animal-free alternative to conventionally sourced PDRN. The controlled production process is designed to support quality consistency, responsible sourcing and scalable supply, helping brands translate advanced biotechnology into commercially viable cosmetic formulations.
For formulators, recombinant PDRN provides an opportunity to develop products that address both immediate appearance and the qualities that help skin remain stronger, more resilient and better able to retain moisture over time. Potential applications include firming serums, barrier-support products and healthy-aging formulations.
As skin longevity becomes a more influential direction in cosmetic product development, active ingredients will increasingly be assessed not only by how effectively they improve visible signs of aging, but also by how comprehensively they support skin structure and function.
Uniproma’s recombinant PDRN reflects this transition, combining visible efficacy, structural support, barrier performance and scalable biotechnology within a single ingredient platform.
Post time: Aug-12-2026